Florian von Groote-Bidlingmaier

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial

Andreas H. Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier et al. · The Lancet · 2012 · 428 citations

Antibiotics, Medicine, Randomised Trial +12

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt et al. · The Lancet · 2015 · 248 citations

Pulmonary Tuberculosis, Phase 2B, Tuberculosis Prevention +9

Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline

Andreas H. Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier et al. · American Journal of Respiratory and Critical Care Medicine · 2015 · 200 citations

Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial

Florian von Groote-Bidlingmaier, R. F. Patientia, Epifanio Sánchez et al. · The Lancet Respiratory Medicine · 2019 · 161 citations · Full text

Increased Frequency of Myeloid-derived Suppressor Cells during Active Tuberculosis and after Recent <i>Mycobacterium tuberculosis</i> Infection Suppresses T-Cell Function

Nelita du Plessis, Laurianne Loebenberg, Magdalena Kriel et al. · American Journal of Respiratory and Critical Care Medicine · 2013 · 158 citations